04.12.26 -- Identify And Manage Leadership Risks Before It's Too Late

Greetings! For this weekend’s hand-selected content from Life Science Leader, I’m highlighting the metaphorical arrows constantly flying at biopharmaceutical leaders — physical/mental, algorithmic, and financial — along with the shielding techniques recommended by experts.

If you’re in a good place with managing the human pressures of company leadership (see the link above), be careful not to get ‘nudged’ off track by a wayward AI; without the right behavioral architecture, the ghost in the machine can run amok, with trial design and pipeline strategy hanging in the balance.

If your mental and mechanical houses are in order, there’s always the funding imperative to manage. On the Business of Biotech, Rahul Aras, Ph.D., CEO at Iterion Therapeutics, spills the tea about capital efficient drug development, and how to progress a novel therapeutic with small funding amounts.

Look below for a curated selection from our partners, and thanks for reading.

Ben Comer   
Chief Editor, Life Science Leader

Citeline validates site selection and drives predictable enrollment through integrated data, feasibility rigor, real world evidence, and patient engagement (More)

Andelyn Biosciences' accelerates ultra-rare gene therapies by pairing parallel execution, rigorous preclinical science, and rapid cGMP AAV manufacturing (More)

AutoCruitment keeps trials moving by unifying outreach, screening, and site operations to reduce delays while protecting quality and diversity (More)

20/20 Onsite explains how to avoid tiny variances in intraocular pressure (IOP) that can make all the difference between a validated treatment response and a failed regulatory submission (More)

Mural Health exposes payment and tax risks in participant compensation, outlining standardization choices to safeguard compliance and trust (More)

CSS shows how closing literacy gaps with AI driven simplification turns informed consent into participation and sustained enrollment momentum (More)

Thermo Fisher Scientific helps mRNA leaders reduce supply risk and costs through smarter raw materials and ecosystem collaboration (More)